Antigen Presentation and Lymphocyte Response in Parkinson's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

95 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-02-28

Study Completion Date

2021-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The way the immune system responds to certain PD-related proteins in PD donors compared to the way it responds in persons without or fewer PD related proteins is not well studied and this study aims to analyze the autoimmune response in each group. The study involves a one time visit involving brief questionnaires and a blood draw of 30 mL (approximately 2 tablespoons) to be collected.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Autonomic, Imaging and Genetic Markers for Parkinson-related Dementia : Longitudinal Assessment of a PD Cohort.

NCT06156917

Parkinson Disease

COMPLETED

Parkinson's Disease Inflammatory Biomarker Profiling

NCT03633513

Parkinson Disease

TERMINATED

Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families

NCT00273351

Parkinson Disease Parkinsonian Syndrome

COMPLETED PHASE2

Relationship Between Immunosuppressive Treatment Status and Clinical Course of Parkinson's Disease

NCT06834191

Parkinson Disease

RECRUITING

A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease

NCT00387075

Parkinson Disease

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The role of the immune response in Parkinson's disease (PD) is controversial. Recent studies show that neurons can present MHC-I (major histocompatibility complex - class 1) molecules and therefore may be susceptible to an attack by immune cells. The investigators anticipate that the results of this study will improve our understanding of the mechanisms of immune mediated neuronal degeneration in PD. Initial results suggest that antigens are presented by neuronal MHC-I in PD, and that this could lead to T-cell mediated neuronal death. The most obvious antigen that could be differentially expressed in PD patients and controls would be alpha-synuclein (-syn): -syn oligomers appear in all Lewy bodies and Lewy neurites and are the hallmark of PD changes in the brain. This study will offer the opportunity to further characterize the immune mediated component of PD, and to continue elucidating the biology that underlies antigen presentation and T-cell cytolytic activity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PD and Controls

50% of the participants will be healthy controls and 50% will be patients diagnosed with Parkinson's disease

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Moderate to advanced PD with classic motor features, and must demonstrate two of the following three: rest tremor, rigidity, or bradykinesia
* Dopaminergic medication benefit (self-reported improvement)
* Age at recruitment: 50 - 90 years
* Age at diagnosis \> 47
* PD duration \> 3 years
* Willingness to have genotyping and genetic studies as part of laboratory research

Exclusion Criteria

* Atypical parkinsonism or other neurological disorders
* Recent history of cancer (past 3 years)
* Autoimmune disease (except thyroid disease)
* On chronic immune-modulatory therapy (e.g. SIT (specific immunotherapy), anti-IgE)
* Inability to provide informed consent

Minimum Eligible Age

50 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes